How licensed distributors are strategically preparing for medical cannabis

Regulatory preparation, analytical standards, batch planning: what distributors do now to be ready on day 1.

Distributors do not want to start from scratch on market-opening day. They need batch pre-reservations, clear analytical standards and legal certainty that production and distribution align with Swissmedic/FOPH requirements.

Waitlist with documented interest for defined batches and volumes

Quarterly regulatory sync call on BtMG, HMG and FOPH developments

Analytical blueprints (cannabinoid, terpene, pesticide, heavy metals, microbiology)

Early involvement in cultivation and genetics planning

30+ licensed distributors from CH/DACH/EU enrolled, 8 with documented batch pre-reservations. First bilateral MOUs being drafted once the regulatory frame is final.

We want to be shippable on day 1 — not start the process on day 90.

Head of Sourcing, EU pharma distributor

Is this already a binding order?

No. The waitlist is a structured interest with volume and batch indication; it becomes binding once the market opens and the right licensing set-up is in place.

Who can enrol?

Only operators with a valid licence in the target country for controlled substances or pharmaceutical distribution.

When does real supply start?

Once the regulatory framework is final and production plus distribution follow a clear compliance path.